ILUS Provides Update on Disclosure Status and OTC Markets Listing
ILUS (OTC: ILUS) provided an update regarding its financial disclosure status and OTC Markets listing position. The company is experiencing delays in completing its 2024 audited financial statements due to multiple complexities, including subsidiary consolidations, acquisitions, divestitures, and the sale of Quality Industrial to a Nasdaq-listed company.
Due to these delays and OTC Markets rules prohibiting multiple overdue filings, ILUS may be temporarily moved to the OTC Expert Market. The company expects to complete its filings before Q4 2025 and is considering filing a Form S-1 registration statement and potentially submitting a Nasdaq listing application.
CEO Nicolas Link attributed the delays to a "perfect storm" of events, including inherited accounting issues, auditor changes, and complex consolidation requirements. Management emphasizes that any OTC downgrade would be temporary and is committed to operating either on the main OTC tier or a national exchange as soon as possible.
ILUS (OTC: ILUS) ha fornito un aggiornamento sullo stato della sua divulgazione finanziaria e sulla posizione nella quotazione OTC Markets. L'azienda sta affrontando ritardi nel completamento dei bilanci finanziari 2024 revisionati a causa di molteplici complessità, tra cui consolidamenti di società controllate, acquisizioni, cessioni e la vendita di Quality Industrial a una società quotata al Nasdaq.
A causa di questi ritardi e delle regole di OTC Markets che vietano più depositi in ritardo, ILUS potrebbe essere temporaneamente spostata nell'OTC Expert Market. L'azienda prevede di completare le sue comunicazioni entro il quarto trimestre del 2025 e sta valutando la presentazione di una dichiarazione di registrazione Form S-1 e la possibile sottomissione di una domanda di quotazione al Nasdaq.
Il CEO Nicolas Link ha attribuito i ritardi a una "tempesta perfetta" di eventi, tra cui problemi contabili ereditati, cambi di revisore e requisiti complessi di consolidamento. La direzione sottolinea che qualsiasi declassamento OTC sarebbe temporaneo ed è impegnata a operare il prima possibile sia nel tier principale OTC che in una borsa nazionale.
ILUS (OTC: ILUS) proporcionó una actualización sobre el estado de su divulgación financiera y su posición en la lista de OTC Markets. La compañía está experimentando retrasos en la finalización de sus estados financieros auditados de 2024 debido a múltiples complejidades, incluyendo consolidaciones de subsidiarias, adquisiciones, desinversiones y la venta de Quality Industrial a una empresa cotizada en Nasdaq.
Debido a estos retrasos y a las reglas de OTC Markets que prohíben múltiples presentaciones atrasadas, ILUS podría ser trasladada temporalmente al OTC Expert Market. La empresa espera completar sus presentaciones antes del cuarto trimestre de 2025 y está considerando presentar una declaración de registro Formulario S-1 y posiblemente someter una solicitud de cotización en Nasdaq.
El CEO Nicolas Link atribuyó los retrasos a una "tormenta perfecta" de eventos, incluyendo problemas contables heredados, cambios de auditor y requisitos complejos de consolidación. La dirección enfatiza que cualquier degradación en OTC sería temporal y está comprometida a operar tan pronto como sea posible en el nivel principal de OTC o en una bolsa nacional.
ILUS (OTC: ILUS)는 재무 공시 상태 및 OTC 마켓 상장 위치에 대한 최신 정보를 제공했습니다. 자회사 통합, 인수, 매각, 그리고 Quality Industrial을 나스닥 상장 기업에 매각하는 등 여러 복잡한 사유로 인해 2024년 감사 재무제표 완성에 지연이 발생하고 있습니다.
이러한 지연과 OTC 마켓 규정상 여러 번의 제출 지연이 금지되어 있어 ILUS는 일시적으로 OTC 전문가 시장(OTC Expert Market)으로 이동될 수 있습니다. 회사는 2025년 4분기 이전에 제출을 완료할 것으로 예상하며, Form S-1 등록신고서를 제출하고 나스닥 상장 신청을 고려하고 있습니다.
CEO 니콜라스 링크는 지연 원인을 상속된 회계 문제, 감사인 교체, 복잡한 통합 요건 등 '완벽한 폭풍' 때문이라고 설명했습니다. 경영진은 OTC 강등이 일시적일 것이라 강조하며, 가능한 한 빨리 주요 OTC 단계나 국가 거래소에서 운영할 것을 약속했습니다.
ILUS (OTC : ILUS) a fourni une mise à jour concernant son statut de divulgation financière et sa position sur le marché OTC. La société rencontre des retards dans la finalisation de ses états financiers audités 2024 en raison de multiples complexités, notamment des consolidations de filiales, des acquisitions, des cessions et la vente de Quality Industrial à une société cotée au Nasdaq.
En raison de ces retards et des règles des marchés OTC interdisant plusieurs dépôts en retard, ILUS pourrait être temporairement déplacée vers l'OTC Expert Market. La société prévoit de compléter ses dépôts avant le quatrième trimestre 2025 et envisage de déposer une déclaration d'enregistrement Formulaire S-1 et potentiellement de soumettre une demande de cotation au Nasdaq.
Le PDG Nicolas Link a attribué les retards à une « tempête parfaite » d'événements, incluant des problèmes comptables hérités, des changements d'auditeurs et des exigences complexes de consolidation. La direction souligne que toute rétrogradation OTC serait temporaire et s'engage à opérer dès que possible soit sur le niveau principal OTC, soit sur une bourse nationale.
ILUS (OTC: ILUS) gab ein Update zum Stand seiner finanziellen Offenlegung und zur Notierung bei den OTC Markets. Das Unternehmen erlebt Verzögerungen bei der Fertigstellung der geprüften Finanzberichte 2024 aufgrund mehrerer Komplexitäten, darunter Konsolidierungen von Tochtergesellschaften, Akquisitionen, Veräußerungen und der Verkauf von Quality Industrial an ein Nasdaq-gelistetes Unternehmen.
Aufgrund dieser Verzögerungen und der OTC Markets-Regeln, die mehrere verspätete Einreichungen verbieten, könnte ILUS vorübergehend in den OTC Expert Market verschoben werden. Das Unternehmen erwartet, die Einreichungen vor dem vierten Quartal 2025 abzuschließen und erwägt die Einreichung einer Form S-1-Registrierungserklärung sowie möglicherweise die Beantragung einer Nasdaq-Notierung.
CEO Nicolas Link führte die Verzögerungen auf eine „perfekte Sturm“ von Ereignissen zurück, darunter übernommene Buchhaltungsprobleme, Wechsel des Prüfers und komplexe Konsolidierungsanforderungen. Das Management betont, dass eine OTC-Abstufung vorübergehend wäre und verpflichtet sich, so bald wie möglich entweder auf der Haupt-OTC-Ebene oder einer nationalen Börse zu operieren.
- Company is actively working to resolve SEC comments and complete audited financials
- Planning potential uplisting to Nasdaq from OTC Markets
- Management has experience with successful registration statements and exchange listings
- Strategic focus on long-term growth and value creation
- Delayed 2024 audited financial statements
- Risk of temporary downgrade to OTC Expert Market
- Multiple complex accounting issues and audit challenges
- Outstanding SEC comments on historical filings need to be addressed
NEW YORK, NY, July 17, 2025 (GLOBE NEWSWIRE) -- Ilustrato Pictures International Inc. (OTC: ILUS) ("ILUS" or the "Company"), a mergers and acquisitions company focused on acquiring and scaling businesses in the public safety and industrial sectors, today provided an update regarding the status of its financial disclosures and listing position on the OTC Markets.
As previously communicated to shareholders, ILUS consolidates multiple subsidiaries, including publicly traded companies, within its financial reporting. As a result, any downstream delays, such as audit transitions, accounting changes, or filing delays at the subsidiary level, have a direct impact on ILUS’s ability to complete its consolidations and audits in a timely manner.
Over the past two years, ILUS has managed a significant number of moving parts, including new acquisitions, divestitures, a complex acquisition unwind, and the mid-period sale of its subsidiary Quality Industrial to a Nasdaq-listed company. These events, combined with a change in auditors and the need to address legacy SEC comments on historical filings, have unfortunately delayed the ILUS’s 2024 audited financial statements.
ILUS is actively working with its audit team and is in discussions with the SEC to cure prior comments through its upcoming financial disclosures. Based on professional guidance, ILUS has been advised not to file unaudited interim financials, but instead to file fully audited financials when complete. While this is the correct regulatory approach, it creates a short-term conflict with OTC Markets rules, which prohibit companies from having multiple overdue filings. As a result, ILUS may be temporarily moved to the OTC Expert Market until the updated filings are submitted.
ILUS is targeting completion of its filings before the beginning of Q4 and reiterates that any such OTC downgrade would be temporary and procedural.
Management is evaluating the potential filing of a Form S-1 registration statement with the SEC, either shortly after or concurrently with those filings. ILUS may also submit a listing application to Nasdaq, given its view that remaining on the OTC Markets provides limited value to shareholders and has become a constraint on long-term growth.
“Disappointingly, we found ourselves in a perfect storm,” said CEO Nicolas Link. “We were navigating multiple acquisitions, some of which came with inherited accounting issues, while also addressing our own outstanding SEC comments. During this period, we changed auditors, unwound a prior acquisition that required reinstated financials, and completed the sale of a subsidiary mid-period, forcing us to halt consolidation partway through the year. All of this created a highly complex and resource-intensive audit environment. We couldn’t begin the parent-level audit work until the downstream issues were resolved, which only occurred a few months ago. Now, the team is fully focused on completing the process, and it's our top priority.”
“Filing a registration statement and pursuing a Nasdaq application is a significant task, but one we've successfully managed several times within the group. While it may take time to clear comments and become effective, it’s an essential step. We cannot stay on the OTC indefinitely; it offers little strategic value and imposes costs without benefit. It’s time to complete this chapter, resolve SEC matters once and for all, and give management the ability to fully execute our 2026 roadmap and unlock the value we’ve worked hard to build.”
If necessary, ILUS will also file the appropriate forms to return to its previous OTC tier immediately following its updated filings. Regardless of the path, ILUS confirms it will not remain on the OTC Expert Market longer than necessary and intends to operate either on the main OTC tier or a national exchange as soon as possible.
ILUS is working diligently to complete the required audits and filings and will continue to provide shareholders with updates as progress is made.
For further information on ILUS, please see its communication channels:
Website: https://ilus-group.com
X: @ILUS_INTL
YouTube: @ILUSInternational
Email: IR@Ilus-Group.com
Source: ILUS
Forward-Looking Statement
Certain information set forth in this press release contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information via official Press Releases, in addition to SEC filings, press releases, Questions & Answers sessions, public conference calls, and webcasts also may take time from time to time. We use these channels as well as social media to communicate with the public about our company, our services, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, considering the SEC's guidance, we encourage investors, the media, and others interested in our company to review the information we post on the following social & media channels: Website: https://ilus-group.com X: @ILUS_INTL
FAQ
Why is ILUS stock at risk of being moved to OTC Expert Market?
When will ILUS complete its delayed financial filings?
What are ILUS's plans for Nasdaq listing?
What caused the delays in ILUS's financial reporting?
How will ILUS resolve its OTC Markets listing issues?
